In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Biogen's current price at $208.87 is substantially below its PERT-weighted fair value of $406.98, indicating a potential undervaluation with near 95% implied upside. Strong liquidity contrasts with weak growth and profitability, raising operational risk despite high valuation confidence. Monte Carlo simulation reveals high volatility and a wide value range, implying elevated uncertainty but low downside risk below the current price.